Press release – 28 Feb 2023
The Laboratory of Adaptive Immunity and Homeostasis, headed by Jan Terje Andersen, at Oslo University Hospital and University of Oslo, is at the forefront of studies on how a broadly expressed receptor named the neonatal Fc receptor (FcRn) acts as regulator of albumin and IgG antibody transport at different body sites.
The research group has signed a framework agreement with Roche Diagnostics GmbH and entered a research collaboration with the aim to gain a deeper understanding on how FcRn-targeted molecules are handled in both in vitro and in vivo systems.
Jan Terje Andersen commented :
“Our laboratory is studying complex biology - knowledge that can translate into design of biologics with favorable binding and transport properties. We are excited to extend our collaboration with a leading company in the global biotech industry and antibody space with unique expertise and a drive to develop and translate innovative solutions into tailored products to meet the patient’s needs”.
The agreement has been negotiated by Inven2.
Article (in Norwegian) on how academia and industry can enter into closer cooperation to develop new medicines:
Fra idé til implementering
For more information about the laboratory, please visit:
The Laboratory of Adaptive Immunity and Homeostasis, headed by Jan Terje Andersen
Twitter: @Andersen JT